Influence of Pro-Qura-generated plans on postimplant dosimetric quality: a review of a multi-institutional database.
The influence of Pro-Qura-generated plans vs. community-generated plans on postprostate brachytherapy dosimetric quality was compared. In the Pro-Qura database, 2933 postplans were evaluated from 57 institutions. A total of 1803 plans were generated by Pro-Qura and 1130 by community institutions. Iodine-125 (125I) plans outnumbered Palladium 103 (103Pd) plans by a ratio of 3:1. Postimplant dosimetry was performed in a standardized fashion by overlapping the preimplant ultrasound and the postimplant computed tomography (CT). In this analysis, adequacy was defined as a V100 > 80% and a D90 of 90% to 140% for both isotopes along with a V150 < 60% for 125I and < 75% for 103Pd. The mean postimplant V100 and D90 were 88.6% and 101.6% vs. 89.3% and 102.3% for Pro-Qura and community plans, respectively. When analyzed in terms of the first 8 sequence groups (10 patients/sequence group) for each institution, Pro-Qura planning resulted in less postimplant variability for V100 (86.2-89.5%) and for D90 (97.4-103.2%) while community-generated plans had greater V100 (85.3-91.2%) and D90 (95.9-105.2%) ranges. In terms of sequence groups, postimplant dosimetry was deemed "too cool" in 11% to 30% of cases and "too hot" in 12% to 27%. On average, no clinically significant postimplant dosimetric differences were discerned between Pro-Qura and community-based planning. However, substantially greater variability was identified in the community-based plan cohort. It is possible that the Pro-Qura plan and/or the routine postimplant dosimetric evaluation may have influenced dosimetric outcomes at community-based centers.
Allen
Zachariah
Z
Wheeling Hospital, Schiffler Cancer Center, Wheeling, WV; Wheeling Jesuit University, Wheeling, WV; Seattle Prostate Institute, Seattle, WA; and Pro-Qura, Seattle, WA.
Merrick
Gregory S
GS
Grimm
Peter
P
Blasko
John
J
Sylvester
John
J
Butler
Wayne
W
Chaudry
Usman-Ul-Haq
UU
Sitter
Michael
M
D024221:Antineoplastic Protocols / Q000592:standards; D001918:Brachytherapy / Q000379:methods / Q000592:standards*; D016208:Databases, Factual; D020000:Decision Support Systems, Clinical; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008297:Male; D010165:Palladium / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy* / Q000601:surgery; D011829:Radiation Dosage; D011868:Radioisotopes / Q000627:therapeutic use; D011873:Radiology Information Systems; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods*; D012015:Reference Standards; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D007457:Iodine Radioisotopes; D011868:Radioisotopes; D010165:Palladium